- Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11:2132–41. doi:10.1080/21645515.2015.1044180.
- Wallace AS, Mantel C, Mayers G, Mansoor O, Gindler JS, Hyde TB. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine. 2014;32:5301–10. doi:10.1016/j.vaccine.2014.07.076.
- Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017;13:2494–502. doi:10.1080/21645515.2017.1362515.
- Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496–500. doi:10.1097/INF.0b013e31805d7f17.
- Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507–12. doi:10.1097/01.inf.0000222413.47344.23.
- Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state medicaid population. Pediatr Infect Dis J. 2009;28:98–101. doi:10.1097/INF.0b013e318187d047.
- Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506–12.
- GlaxoSmithKline Biologicals sa. INFANRIX-hexa summary of product characteristics. Rixensart (Belgium), 2000.
- Sanofi Pasteur Europe. HEXYON summary of product characteristics. Marcy l’Etroile (France): European Medicines Agency; 2013.
- MCM vaccine B. V. VAXELIS summary of product characteristics. Leiden (The Netherlands): European Medicines Agency; 2019.
- Euopean Medicines Agency. Assessment report. Hexyon. 2013.
- European Medicines Agency. 2015. Assessment report for paediatric studies submitted according to article 46 of the regulation (EC) No 1901/2006. Infanrix® Hexa.
- Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36:209–15. doi:10.1097/INF.0000000000001406.
- Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 2016;34:3810–16. doi:10.1016/j.vaccine.2016.05.054.
- Collett D. Modelling binary data. London, UK: Chapman & Hall/CRC; 2003.
- Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010;17:1055–65. doi:10.1128/CVI.00131-10.
- Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907–16. doi:10.1016/s0264-410x(98)00227-8.
- Kohberger RC, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine. 2008;26:3516–21. doi:10.1016/j.vaccine.2008.04.016.
- But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008;26:6587–91. doi:10.1016/j.vaccine.2008.09.034.
- Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, Bell BP. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27:881–85. doi:10.1097/INF.0b013e31817702ba.
- Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu S-N, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158–66. doi:10.1016/j.vaccine.2005.03.017.
- Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958–64. doi:10.1016/j.vaccine.2007.06.059.
- Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009;27:1858–62. doi:10.1016/j.vaccine.2009.01.027.
- Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet J-M. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat. 2011;18:369–75. doi:10.1111/j.1365-2893.2010.01312.x.
- Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, Mrazek J, Hozakova L, Zjevikova A, Pliskova L. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395–400. doi:10.1007/s15010-010-0039-7.
- Su F-H, Cheng S-H, Li C-Y, Chen J-D, Hsiao C-Y, Chien -C-C, Yang Y-C, Hung -H-H, Chu F-Y. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085–90. doi:10.1016/j.vaccine.2007.09.013.
- van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2:e753. doi:10.1371/journal.pone.0000753.
- van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey S, Jeffries D, Hall A, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis. 2006;193:1528–35. doi:10.1086/jid.2006.193.issue-11.
- Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404–09. doi:10.1016/j.jinf.2008.08.008.
- Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin. Infect. Dis. 2011;53:68–75. doi:10.1093/cid/cir270.
- Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al. Antibody levels and protection after hepatitis b vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214:16–22. doi:10.1093/infdis/jiv748.
- Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball M, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214:273–80. doi:10.1093/infdis/jiw142.
- Zanetti AR, Romano L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis. 2010;10:755–61. doi:10.1016/S1473-3099(10)70195-X.
- Zanetti A, Parlato A, Romano L, Desole MG, Ferrera G, Giurdanella F, Zuliani M, Richard P, Thomas S, Fiquet A. Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy. Vaccine. 2012;30:5770–75. doi:10.1016/j.vaccine.2012.06.078.
- Giambi C, Bella A, Barale A, Montu D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008;8:100. doi:10.1186/1471-2334-8-100.
- Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, et al. Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin. 2009;5:592–98. doi:10.4161/hv.9051.
- Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine. 2000;18(Suppl 1):S35–8. doi:10.1016/s0264-410x(99)00460-0.
- Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis. 2016;214:1–3. doi:10.1093/infdis/jiv750.
- Robert Koch-Institut. Statement of the German standing committee on vaccination at the RKI recommendations of the standing committee on vaccination (STIKO) at the robert koch institute – 2017/2018. Epidemiologisches Bull. 24 of August 2017. 2017;34:333–76.
- Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine. 2008;26:3142–52. doi:10.1016/j.vaccine.2007.11.096.
- Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, HogenEsch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine. 2009;27:888–92. doi:10.1016/j.vaccine.2008.11.078.
- Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM, Nadig KB, Liska V, Schödel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates. Vaccine. 2012;30:1476–80. doi:10.1016/j.vaccine.2011.12.095.
- Gilbert CL, Klopfer SO, Martin JC, Schodel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin. 2011;7:1336–42. doi:10.4161/hv.7.12.18333.
- Gilbert CL, Stek JE, Villa G, Klopfer SO, Martin JC, Schodel FP, Bhuyan PK. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients. Vaccine. 2014;32:6521–26. doi:10.1016/j.vaccine.2014.09.015.
- Vesikari T, Martin JC, Liss CL, Liska V, Schodel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 2011;30:e109–13. doi:10.1097/INF.0b013e31821ed1a4.
- Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin. 2009;5:92–97. doi:10.4161/hv.5.2.6587.
- Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96:548–57.
- Plotkin SA. Complex correlates of protection after vaccination. Clin. Infect. Dis. 2013;56:1458–65. doi:10.1093/cid/cit048.
- Queenan AM, Dowling DJ, Cheng WK, Fae K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, et al. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. Vaccine. 2019;37:80–89. doi:10.1016/j.vaccine.2018.11.028.
- Gorringe AR, Vaughan TE. Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert Rev Vaccines. 2014;13:1205–14. doi:10.1586/14760584.2014.930667.
- European Centre for Disease Prevention and Control. Vaccine schedules in all coutries of the European Union. 2018.
- Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, UNITED STATES, 2018. 2018.
Open access
2,377
Views
6
CrossRef citations to date
0
Altmetric
Research Paper
Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines
Timo Vesikaria Department of Pediatrics, University of Tampere, Tampere, FinlandView further author information
, Jin Xub Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USAView further author information
, David R. Johnsonc Sanofi Pasteur, Swiftwater, PA, USAView further author information
, Jessie Hallb Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USAView further author information
, Tomáš Marčekd MCM Vaccine B. V., Leiden, The Netherlands
https://orcid.org/0000-0003-0920-4192View further author information
Michelle G. Goveiab Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USAView further author information
, Camilo J. Acostab Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
https://orcid.org/0000-0002-2313-3493View further author information
Andrew Wen-Tseng Leeb Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
View further author information
show allView further author information
Pages 867-874
|
Received 24 Jun 2019, Accepted 21 Sep 2019, Published online: 05 Nov 2019
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.